Pharmacogenomics: Why is everyone talking about DPYD?
Dec. 10, 2025
11 a.m.–Noon CT
Cost
Free for all participants.
Overview
This presentation will introduce attendees to the essential concepts of pharmacogenomics and its impact on oncology, with a special focus on the significance of DPYD testing. Participants will be able to discuss pharmacogenomics, understand the importance of DPYD testing in cancer care, and review the benefits and drawbacks of sequencing-based approaches in pharmacogenomic testing.
Presenter
Ann Moyer, M.D., Ph.D.
Professor of Laboratory Medicine and Pathology
Assistant Professor of Pharmacology
Vice Chair of the Hereditary Practice
Division of Laboratory Genetics and Genomics
Mayo Clinic, Rochester, Minnesota
Learning objectives
Upon completion of this activity, participants should be able to:
- Define pharmacogenomics.
- Explain why DPYD testing is important in oncology.
- Debate the pros and cons of sequencing-based pharmacogenomics.
Intended audience
This webinar is appropriate for laboratory leaders, healthcare providers, and other laboratory personnel who are interested in innovations and the future direction of lab medicine.
Credit
The following types of credit are offered for this event:
ASCLS P.A.C.E.®
Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of 1.0 P.A.C.E.® contact hour.
State of Florida
Mayo Clinic Laboratories is approved as a Continuing Education Accrediting Agency for the Clinical Laboratory Sciences for the State of Florida. Florida Board of Clinical Laboratory Personnel has designated this program for General credit. This program has been approved for 1.0 contact hour.
To obtain credit
1. Register for and participate in the program.
2. Complete the evaluation that will be sent to you after the program.
3. Generate and print your certificate(s).
Level of instruction for this program is intermediate.
Faculty disclosure
Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.
Questions
Contact us: mcleducation@mayo.edu
